See more : Mineros S.A. (MNSAF) Income Statement Analysis – Financial Results
Complete financial analysis of Cardiovascular Systems, Inc. (CSII) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cardiovascular Systems, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Forian Inc. (FORA) Income Statement Analysis – Financial Results
- Marimekko Oyj (MEKKO.HE) Income Statement Analysis – Financial Results
- Prada S.p.A. (PRDSF) Income Statement Analysis – Financial Results
- Elsoft Research Berhad (0090.KL) Income Statement Analysis – Financial Results
- SRH Total Return Fund, Inc. (BIF) Income Statement Analysis – Financial Results
Cardiovascular Systems, Inc. (CSII)
About Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc., a medical technology company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products comprising catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary orbital atherectomy systems (OAS), a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. In addition, it offers guidewires, catheters, balloons, embolic protection system, and other OAS support products. Cardiovascular Systems, Inc. has a partnership with Chansu Vascular Technologies, LLC to develop novel peripheral and coronary everolimus drug-coated balloons. The company was formerly known as Shturman Cardiology Systems, Inc. and changed its name to Cardiovascular Systems, Inc. in January 2003. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in Saint Paul, Minnesota.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 236.22M | 258.97M | 236.55M | 248.02M | 217.04M | 204.91M | 178.18M | 181.54M | 136.61M | 103.90M | 82.49M | 78.78M | 64.83M | 56.46M | 58.57M | 15.99M | 441.00K | 834.00K | 726.00K | 0.00 |
| Cost of Revenue | 63.44M | 61.13M | 48.76M | 47.68M | 39.48M | 39.44M | 35.42M | 39.52M | 31.04M | 24.38M | 19.22M | 16.28M | 15.00M | 16.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 172.78M | 197.84M | 187.79M | 200.34M | 177.56M | 165.47M | 142.76M | 142.02M | 105.57M | 79.52M | 63.27M | 62.50M | 49.83M | 40.27M | 58.57M | 15.99M | 441.00K | 834.00K | 726.00K | 0.00 |
| Gross Profit Ratio | 73.14% | 76.39% | 79.39% | 80.78% | 81.81% | 80.75% | 80.12% | 78.23% | 77.28% | 76.53% | 76.71% | 79.34% | 76.86% | 71.32% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 36.72M | 41.06M | 43.36M | 33.46M | 26.76M | 22.91M | 25.93M | 30.98M | 21.07M | 15.22M | 11.37M | 8.94M | 10.28M | 14.68M | 43.31M | 38.30M | 29.18M | 16.28M | 0.00 | 2.52M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 167.70M | 148.57M | 144.10M | 162.54M | 143.68M | 117.99M | 86.72M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 170.53M | 167.50M | 169.97M | 167.70M | 148.57M | 144.10M | 162.54M | 143.68M | 117.99M | 86.72M | 66.37M | 62.37M | 62.45M | 59.82M | 13.02M | 12.19M | 5.33M | 2.99M | 0.00 | 1.28M |
| Other Expenses | 1.34M | 1.22M | 1.23M | 760.00K | -390.00K | -164.00K | 53.00K | -162.00K | -706.00K | -671.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 208.59M | 209.78M | 214.56M | 201.16M | 175.33M | 167.01M | 188.48M | 174.66M | 139.06M | 101.93M | 77.74M | 71.31M | 72.73M | 74.50M | 56.33M | 50.48M | 34.51M | 19.28M | 0.00 | 3.79M |
| Cost & Expenses | 272.03M | 270.91M | 263.32M | 248.84M | 214.81M | 206.45M | 223.90M | 214.18M | 170.10M | 126.32M | 96.96M | 87.59M | 87.73M | 90.69M | 56.33M | 50.48M | 34.51M | 19.28M | 0.00 | 3.79M |
| Interest Income | 817.00K | 499.00K | 1.74M | 2.44M | 1.33M | 383.00K | 0.00 | 0.00 | 0.00 | -1.62M | 5.00K | 12.00K | 402.00K | 3.38M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.63M | 1.74M | 1.97M | 1.68M | 1.72M | 500.00K | 0.00 | 23.00K | 1.03M | 1.35M | 2.32M | 1.42M | 1.44M | 2.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.34M | 1.22M | 1.23M | 3.45M | 3.93M | 4.14M | 3.92M | 2.32M | 1.37M | 973.00K | 872.00K | 716.00K | 600.00K | 470.00K | 2.25M | 683.00K | 1.29M | 1.30M | 0.00 | 0.00 |
| EBITDA | -34.46M | -10.72M | -25.54M | -825.00K | 2.23M | -1.54M | -35.35M | -32.64M | -33.49M | -22.42M | -14.47M | -8.81M | -22.33M | -35.07M | -963.00K | -39.07M | -32.78M | -16.68M | 726.00K | -3.79M |
| EBITDA Ratio | -14.59% | -4.14% | -10.80% | -0.33% | 1.03% | -0.75% | -19.84% | -17.98% | -24.51% | -21.58% | -17.54% | -11.18% | -34.44% | -62.12% | -1.64% | -244.37% | -7,431.97% | -1,999.76% | 100.00% | 0.00% |
| Operating Income | -35.81M | -11.93M | -26.77M | -825.00K | -1.70M | -1.54M | -56.08M | -32.64M | -33.49M | -22.42M | -14.47M | -8.81M | -22.90M | -34.23M | 2.24M | -34.49M | -34.07M | -18.44M | 726.00K | -3.79M |
| Operating Income Ratio | -15.16% | -4.61% | -11.32% | -0.33% | -0.78% | -0.75% | -31.47% | -17.98% | -24.51% | -21.58% | -17.54% | -11.18% | -35.32% | -60.63% | 3.82% | -215.75% | -7,725.17% | -2,211.27% | 100.00% | 0.00% |
| Total Other Income/Expenses | -817.00K | -1.24M | -233.00K | 760.00K | 3.54M | -164.00K | 53.00K | -185.00K | -1.80M | -1.62M | -2.32M | 0.00 | 28.00K | 1.31M | 5.45M | 5.26M | 399.00K | -797.00K | 0.00 | 0.00 |
| Income Before Tax | -36.62M | -13.17M | -27.01M | -65.00K | 1.84M | -1.71M | -56.02M | -32.82M | -35.29M | -24.04M | -15.44M | 0.00 | -22.87M | -32.93M | 7.69M | -29.24M | -33.67M | -19.24M | 0.00 | 0.00 |
| Income Before Tax Ratio | -15.50% | -5.09% | -11.42% | -0.03% | 0.85% | -0.83% | -31.44% | -18.08% | -25.83% | -23.14% | -18.72% | 0.00% | -35.28% | -58.31% | 13.13% | -182.86% | -7,634.69% | -2,306.83% | 0.00% | 0.00% |
| Income Tax Expense | 310.00K | 252.00K | 231.00K | 190.00K | 132.00K | 86.00K | 6.39M | -2.30M | -333.00K | 344.00K | 479.00K | 1.60M | 1.01M | -25.12M | -5.45M | -5.25M | 0.00 | 797.00K | 13.95M | 3.76M |
| Net Income | -36.93M | -13.42M | -27.24M | -255.00K | 1.71M | -1.79M | -56.02M | -32.82M | -35.29M | -24.04M | -16.79M | -11.13M | -23.90M | -9.11M | 7.69M | -29.25M | -33.67M | -19.24M | -13.95M | -3.76M |
| Net Income Ratio | -15.63% | -5.18% | -11.51% | -0.10% | 0.79% | -0.87% | -31.44% | -18.08% | -25.83% | -23.14% | -20.35% | -14.12% | -36.87% | -16.14% | 13.13% | -182.94% | -7,634.69% | -2,306.83% | -1,921.49% | 0.00% |
| EPS | -0.94 | -0.35 | -0.79 | -0.01 | 0.05 | -0.06 | -1.72 | -1.04 | -1.25 | -1.11 | -0.93 | -0.70 | -1.62 | -1.13 | 2.90 | -21.03 | -323.00 | -257.79 | -208.20 | -53.01 |
| EPS Diluted | -0.94 | -0.35 | -0.79 | -0.01 | 0.05 | -0.06 | -1.72 | -1.04 | -1.25 | -1.11 | -0.93 | -0.70 | -1.62 | -1.13 | 2.80 | -21.03 | -323.00 | -257.79 | -208.20 | -53.01 |
| Weighted Avg Shares Out | 39.23M | 38.83M | 34.28M | 33.54M | 33.15M | 32.37M | 32.54M | 31.55M | 28.30M | 21.69M | 18.04M | 15.92M | 14.75M | 8.07M | 2.67M | 1.39M | 104.24K | 74.63K | 67.00K | 70.97K |
| Weighted Avg Shares Out (Dil) | 39.23M | 38.83M | 34.28M | 33.54M | 33.61M | 32.37M | 32.54M | 31.55M | 28.30M | 21.69M | 18.04M | 15.92M | 14.75M | 8.07M | 2.77M | 1.39M | 104.24K | 74.63K | 67.00K | 70.97K |
Abbott Buying Cardiovascular Systems: Details (ABT)
Abbott (NYSE: ABT) is buying Cardiovascular Systems (CSI). These are the details.
Cardiovascular Systems (CSII) Q2 Earnings, Revenues Miss
With the announcement of the merger agreement with Abbott, Cardiovascular Systems (CSII) refrains from providing any update on the 2023 guidance.
SHAREHOLDER ALERT: Weiss Law Investigates Cardiovascular Systems, Inc.
NEW YORK , Feb. 9, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Cardiovascular Systems, Inc. ("Cardiovascular Systems" or the "Company") (NASDAQ: CSII), in connection with the...
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Cardiovascular Systems, Inc. Buyout
Wilmington, Delaware--(Newsfile Corp. - February 9, 2023) - Rigrodsky Law, P.A. is investigating Cardiovascular Systems, Inc. ("Cardiovascular") (NASDAQ: CSII) regarding possible breaches of fiduciary duties and other violations of law related to Cardiovascular's agreement to be acquired by Abbott Laboratories....
Why Cardiovascular Systems Stock Is Soaring Today
The medtech company has agreed to a buyout offer from Abbott Laboratories.
Why Is Cardiovascular Systems (CSII) Stock Up 48% Today?
Cardiovascular Systems (NASDAQ: CSII ) stock is rising higher on Thursday following news that Abbott (NYSE: ABT ) intends to acquire the company. That deal has Abbott offering to buy Cardiovascular Systems for $890 million.
CSII STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Cardiovascular Systems, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Cardiovascular Systems, Inc. (NASDAQ: CSII) to Abbott Laboratories for $20.00 per common share is fair to Cardiovascular shareholders. Halper Sadeh encourages Cardiovascular shareholders to...
CSII STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Cardiovascular Systems, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Cardiovascular Systems, Inc. (NASDAQ: CSII) to Abbott Laboratories for $20.00 per common share is fair to Cardiovascular shareholders. Halper Sadeh encourages Cardiovascular shareholders to...
Cardiovascular Systems shares jump after deal to be bought by Abbott for $890 million
Cardiovascular Systems CSII, -1.99% shares rose 47% to $19.58 in early premarket trade after Abbott ABT, -1.60% agreed to buy the company for $890 million, or $20 per share. CSI is a leader in devices for atherectomy, a minimally invasive...
Cardiovascular Systems (CSII) Reports Q2 Loss, Misses Revenue Estimates
Cardiovascular Systems (CSII) delivered earnings and revenue surprises of -33.33% and 2.70%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Source: https://incomestatements.info
Category: Stock Reports